Peptide Therapy: Is It Worth It?

You're spending $200–600 a month. You're injecting something into your body. You want to know if it's actually going to do anything. Fair.

Here's the honest answer: peptide therapy works really well for some people, reasonably well for others, and isn't the right move for a meaningful percentage of people who try it. The difference usually comes down to three things — what you're treating, which peptide you're using, and how much evidence backs it up.

Where the Evidence Is Strongest

Weight management with GLP-1 peptides

This is the clearest win in peptide therapy. Semaglutide and tirzepatide have extensive Phase III clinical trial data. We're talking thousands of participants, peer-reviewed publications, FDA approval.

The numbers: semaglutide (Wegovy) showed an average of 14.9% body weight loss over 68 weeks in the STEP 1 trial. Tirzepatide (Zepbound) hit 20.9% in the SURMOUNT-1 trial at the highest dose. These aren't marginal results. For someone weighing 250 pounds, that's 37–52 pounds lost.

Is it worth $200–500/month? If you have significant weight to lose and haven't succeeded with diet and exercise alone — probably yes. The average American spends $219/month on dining out. Replacing that spending with effective, physician-supervised weight management changes your health trajectory for decades.

Growth hormone support with sermorelin

Sermorelin is well-studied. It's been FDA-approved (as a diagnostic agent) and has decades of clinical use. It stimulates your body to produce its own growth hormone rather than injecting synthetic GH directly.

Most patients report better sleep within 2–4 weeks. Body composition changes — less fat, more lean muscle — typically take 2–3 months. Improvements in skin, energy, and recovery happen somewhere in between.

Is it worth $300–600/month? For adults with documented low growth hormone production, the evidence supports it. For healthy 30-year-olds hoping to "optimize" already-normal GH levels, the benefit is less clear and the cost harder to justify.

Sexual wellness with PT-141

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder. Phase III trials showed statistically significant improvement in sexual desire and reduction in distress. It works through a different mechanism than PDE5 inhibitors (like Viagra) — it acts on brain pathways involved in desire, not blood flow.

Is it worth $100–300/month? For people with diagnosed sexual desire disorder who haven't responded to other approaches, the evidence supports it. This is an FDA-approved medication with real clinical trial data behind it.

Where the Evidence Is Promising But Early

Recovery with BPC-157

BPC-157 has an impressive body of preclinical research — hundreds of studies showing accelerated healing in tendons, ligaments, muscle, and gut tissue. The catch: almost all of this is animal data. Human clinical trials are limited.

Anecdotal reports from patients and clinicians are consistently positive. But anecdote isn't evidence. We don't have the large-scale human trials that tell us exactly how well it works, for whom, at what dose, and with what side effect profile.

Is it worth $150–400/month? If you have a nagging injury that isn't responding to conventional treatment, and your physician recommends it based on the available evidence — it could be. But go in with eyes open about where the evidence stands.

Cognitive and cellular health with NAD+

NAD+ is involved in hundreds of cellular processes. Levels decline with age. Supplementing NAD+ through IV, injection, or nasal spray aims to restore what time takes away. The basic science is compelling. The clinical evidence for specific outcomes in humans is still developing.

Is it worth $200–500/month? Harder to quantify. Some patients swear by it for energy and mental clarity. Others notice little difference. If you're considering it, give it a fair trial (2–3 months) and track how you feel. If you don't notice a meaningful difference, stop.

Who Sees the Best Results

After talking with physicians who've prescribed thousands of peptide protocols, a pattern emerges. The patients who get the most out of peptide therapy share a few traits:

• They have a specific problem. "I need to lose 40 pounds" works better than "I want to feel optimized." Vague goals produce vague results.
• They match the right peptide to the right condition. GLP-1 for weight. Sermorelin for growth hormone deficiency. PT-141 for sexual desire. The precision matters.
• They combine peptides with lifestyle changes. Peptides aren't magic pills. GLP-1s work better with dietary changes. Sermorelin works better with exercise and sleep hygiene. The peptide is a tool, not a substitute.
• They commit to 3+ months. Most peptides need time. If you quit after 3 weeks, you won't know if it was going to work.
• They work with a real physician. Someone who adjusts dosing, monitors labs, and makes changes based on your response. Not someone who writes one prescription and disappears.

Who Shouldn't Bother

We'd rather lose the sale than waste your money. Here's who peptide therapy probably isn't for:

• People looking for a magic bullet. If you want to inject something and change nothing else about your life, you'll be disappointed. Peptides amplify effort. They don't replace it.
• People with unrealistic timelines. "I want to lose 30 pounds in a month" isn't how biology works. Even the best GLP-1 protocols take 3–6 months for major results.
• People who can't afford it comfortably. Peptide therapy costs $150–600/month. If that puts real financial strain on you, the stress might negate the benefit. Don't go into debt for peptides.
• People with conditions that are better treated other ways. If your doctor says you need thyroid medication, peptides aren't a substitute. If you have clinical depression, peptides aren't a substitute for therapy and SSRIs. Use the right tool for the problem.
• People who won't stick with it. A month isn't enough time. If you know you'll try it for 3 weeks and stop, save your money.

The ROI Framing

Think about what you're comparing the cost to:

• Weight loss programs like Noom ($199/year) or WW ($25–45/month) have modest efficacy — 3–5% body weight loss on average. GLP-1 peptides deliver 15–20% at $200–500/month. The cost-per-pound-lost math favors peptides significantly.
• Gym memberships + personal training run $200–400/month. Adding a peptide protocol that improves recovery and body composition might make that investment more productive.
• The cost of staying unhealthy. Type 2 diabetes costs an average of $9,601 per year in direct medical expenses above what a person without diabetes spends. Heart disease is even more. If peptide therapy helps you avoid those outcomes, the math speaks for itself.

That said — don't let ROI framing talk you into something you don't need. The best investment is always the basics: sleep, diet, exercise, stress management. Peptides are a tool you add when the basics aren't enough.

How to Decide

Ask yourself these questions:

1. Do I have a specific health goal that an evidence-backed peptide addresses?
2. Have I tried lifestyle approaches first?
3. Can I comfortably afford 3–6 months of treatment?
4. Am I willing to work with a physician and follow a protocol?
5. Am I okay with the possibility that it might not work for me specifically?

If you answered yes to all five, peptide therapy is worth exploring. Your first consultation is the best way to get personalized guidance. A good physician will tell you whether you're a candidate — and they'll tell you if you're not.